Georges WagnièresGeorges Wagnières received his diploma degree (MSc) in physics from the University of Lausanne, Switzerland, in 1986. He obtained his doctorate in science (PhD) in physics (Biomedical optics) from the Swiss Federal Institute of Technology at Lausanne (EPFL) in 1992 and did a postdoctoral work in the Wellman Laboratories of Photomedicine (Harvard Medical School), Boston, USA, from 1993 to 1994. He also obtained a Master degree in Management of Technology delivered by the Ecole des Hautes Etudes Commerciales (HEC) of Lausanne University and the EPFL in 2001. Georges Wagnières manages a research group active in the fields of: - Detection of early superficial cancers by fluorescence imaging. - Characterization of early superficial cancers by high magnification narrow band imaging. - In vivo and in vitro measurement of the vascular and tissular oxygen concentration by time-resolved luminescence spectroscopy and imaging. - Preclinical and clinical study of new photosensitizers for photodynamic therapy (PDT). - Treatment of neurodegenerative conditions (Alzheimer, Parkinson's diseases) by photobiomodulation. - Preclinical and clinical photodynamic therapy of inflammatory bowel diseases and atheroscerotic plaque. - Improvement of the selective vascular extravasation of chemotherapeutic agents by PDT. - Monitoring the light dosimetry during PDT by fluorescence spectroscopy and imaging. - Monitoring laser treatments of the retina by reflectance imaging. - Light dosimetry and tissue optical spectroscopy. - Radiometry. - Development of light delivery systems for biomedical applications. Georges Wagnières is also co-founder and was chairman of one spin-off companies: - Medlight SA, founded in July 1997, which develops, produces and commercializes light distributors for photodynamic therapy. Georges Wagnières has currently authored more than 235 papers (more than 150 in international journals with review board) and is inventor of 18 patents. He supervised 12 PhD students up to now, and currently teaches biomedical optics and photomedicine in master programs and doctoral schools. In addition, he gives the course entitled "Physique Générale I" to biology first year students registered to the Biology School of the Lausanne's University. MAIN PUBLICATIONS Please visit: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ Paul Joseph DysonPaul Dyson joined the Institute of Chemical Sciences and Engineering at the EPFL in 2002 where he heads the Laboratory of Organometallic and Medicinal Chemistry and between 2008 and 2016 chaired the Institute. He has won several prizes including the Werner Prize of the Swiss Chemical Society in 2004, the Award for Outstanding Achievements in Bioorganometallic Chemistry in 2010, the Centennial Luigi Sacconi Medal of the Italian Chemical Society in 2011, the Bioinorganic Chemistry Award of the Royal Society of Chemistry in 2015, the European Sustainable Chemistry Award of the European Chemical Society in 2018 and the Green Chemistry Award from the Royal Society of Chemistry in 2020. He is also a Clarivate Highly Cited Researcher and has an H-index >110 (web of science and google scholar). He was elected a Fellow of the Royal Society of Chemistry in 2010, a Fellow of the European Academy of Science in 2019 and a life-long fellow of the American Association for the Advancement of Science in 2020. Over the years he has held visiting professorships at the University of Bourgogne, University of Pierre et Marie Curie, University of Vienna, University of Rome Tor Vergara, Chimie Paristech and Shangai Jiao Tong University.Since 2016 he has been Member of the Council of the Division of Mathematics, Natural and Engineering Sciences at the Swiss National Science Foundation.Between 2016-2021 he has been Member of the Council of the Division of Mathematics, Natural and Engineering Sciences at the Swiss National Science Foundation. In 2021 he was appointed Dean of the Faculty of Basic Sciences.
Ute KochExpertise
SCIENTIFIC EXPERTISESCurrent Molecular Biology and Cloning, Developmental Biology, Cellular and Molecular Immunology, Lymphocyte Maturation and Lineage Commitment, Thymic Selection, Hematopoietic Stem Cell Biology, Bone Marrow Transplantation, Graft-versus-Host Disease, Skin Transplantation, T Lymphocyte Subset Induction (Th1 - Th2, Cytokine Regulation), Extensive Knowledge in Flow CytometryIT SKILLSMicrosoft-Office: Word, Excel, PowerPoint.File Maker Pro: Database design and management.Flow cytom
Solomzi MakohlisoTeaching & PhD Courses Development engineering ENV-470 This course teaches the fundamentals of technologies for development (Development Engineering) to design, pilot, and deploy appropriate, affordable and robust technologies to address sustainable development challenges and especially those related to extreme poverty in Low-income settings. Science, Technology & Vulnerability HUM-287 This course explores how science and technology can address extreme vulnerability caused by
Klaus Benedikt SchönenbergerVision: Scientific research and technology development can be mobilized to help the poorest and most vulnerable in this world. Klaus Schönenberger obtained an MSc in Microengineering (1993), followed by a PhD (1996) from the Swiss Federal Institute of Technology in Lausanne (EPFL). After a post-doc at Lawrence Livermore National Laboratory in California, he spent over 10 years in the medical devices industry in leading positions such as Vice-President of Worldwide R&D in a 100mcompanyandGlobalVice−ResidentofResearchandTechnologyina1bn company. In 2009, as he was working for a medical devices company, he received a shock: he realized that there is a huge imbalance in access to medical technology in industrialized versus low and middle-income countries. After a closer look, he discovered that he imbalance’s main cause is a mismatch between existing technologies and business models, with those needed in low and middle-income countries. He decided to leave industry and, in 2009, he co-founded the EssentialMed Foundation, an innovative non-profit venture. In 2011, realizing that both technology and business models needed a profound rethinking, he joined EPFL where he launched EssentialTech, an initiative inspired by the philosophy of EssentialMed but expanded to a much wider portfolio of "essential" technologies. The university-wide program aims to develop innovative technologies and business models, for the benefit of sustainable development in low and middle-income countries. In this role, he has already launched and overseen a dozen large projects. Major Humanitarian actors such as the ICRC, MSF and Terre des Hommes took notice of the innovative approach proposed, and decided to collaborate in 2015-2016. This has resulted notably in the joint creation between EPFL and ICRC, of the Humanitarian Tech Hub at EPFL. In May 2017, Klaus directed and launched a MOOC(Massive Open Online Course) entitled “Technology Innovation for Sustainable Development” which aims to spread the unique methodology and approach worldwide. As of today, more than 6000 people have enrolled. In 2018 a first spin-off company was created. Award winning Pristem SA will deploy an innovative new digital xray imaging system, specifically designed for low-income contexts. In December 2018, the creation of the EssentialTech centre was announced by EPFL's presidency, and Klaus is now the Centre's director. Another spin-off of the EssentialTech Centre is the company HMCare, launched in 2020, which is deploying a transparent surgical mask. Hubert GiraultEducation: 1979 - Engineering diploma from Grenoble Institute of Technology. FRANCE. 1982 - PhD- Department of Chemistry, University of Southampton. Thesis entitled : Interfacial studies using drop image processing techniques. Positions : 1982 - 1984 SERC Research Fellow. University of Southampton. 1984 - 1985 CNRS Research Fellow. University of Southampton. 1985 - 1992 Lecturer in Physical Chemistry, University of Edinburgh. 1992 - Professor of Physical Chemistry, Ecole Polytechnique Fédérale de Lausanne. 2011 - 2014 Dean of Bachelor and Master studies Hubert Girault is the author of 2 textbooks, the co-author of about 600 scientific publications with more than 20'000 citations and the co-inventor of more than 15 patents. During his academic career, he has supervised 70 PhD students. 30 alumni of his laboratory are now Professors. Honours: Faraday medal 2006, Royal Society of Chemistry, Fellow of the International Society of Electrochemistry 2007, Reilley Award 2015. Fellow of the Electrochemical Society (USA), Shikata International medal, Polarography Society of Japan. Associate editor of Chemical Science
Valentin SimeonovResearchComplete publication list Valentin SimeonovCollaborateur scientifique- EPFL ENAC EFLUMList of publicationsRefereed 1. V. Mitev, V. Simeonov, and I. Grigorov, "Model experiment in measuring the temperature and concentration of water vapours in air by spontaneous Raman scattering", Bulg. J. Phys. 9, No 5, pp. 549-558, (1982)2. V. Mitev, V. Simeonov, and I. Grigorov, ”Atmospheric gases temperature measurements by pure rotational Raman scattering”, Russian Journal of Applied Spectroscopy, 39,
Giovanni De MicheliExpertise
Design technologies for integrated systems on silicon, such as synthesis, hw/sw codesign and low-power design, as well as systems on heterogeneous platforms including electrical and biological components.
Scientific Director of EcoCloud Center at EPFL
Directing activities towards creating sustainable computation including AI.Designing energy-savvy data centers and edge devices.
More information
Please read http://si2.epfl.ch/~demichel/
Giovanni De Micheli is a research scientist in electronics and Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Harm-Anton KlokExpertise
Polymer design at nanoscaleBiologically-inspired polymers
Mission
Research at the Laboratory of Polymer (LP) focuses on the development of novel advanced polymeric materials with potential applications in optics, electronics or medicine. The philosophy is that precise control over nanoscale structure is an important prerequisite to tailor polymer properties. To this end, a “bottom-up” approach is followed, which starts with designing a new material at the molecular level, in order to be able to pr
Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
